Intrathecal Enzyme Replacement Therapy For Patients With Mucopolysaccharidosis Type I (Hurler Syndrome)
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2018
Price : $35 *
At a glance
- Drugs Laronidase (Primary)
- Indications Mucopolysaccharidosis I
- Focus Therapeutic Use
- 30 Nov 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 03 Dec 2017 Planned End Date changed from 10 Nov 2017 to 10 Nov 2018.